Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | KDM4B | O94953 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | HBB | P68871 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Purine SCHEMBL3157 | 0.98 | — | — | |
| Purine SCHEMBL29456595 | 0.98 | — | — | |
| Purine SCHEMBL2120547 | 0.98 | KDM4A (0.38) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL5578775 | 0.95 | KDM4A (0.37) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL5611476 | 0.95 | KDM4A (0.37) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL9603027 | 0.95 | — | — | |
| Purine SCHEMBL311318 | 0.95 | KDM4A (0.37) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL6438162 | 0.95 | KDM4A (0.37) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL7787135 | 0.95 | KDM4A (0.37) | KDM4AKDM4BKDM5CKDM4CKDM5B | |
| Purine SCHEMBL9057416 | 0.95 | KDM4A (0.37) | KDM4AKDM4BKDM5CKDM4CKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109294976-A | A kind of serum free medium for supporting HEK293 cell suspension cultures | 王晓柯 | 2019-02-01 | — | — | CN | claimed |
| CN-107236708-A | A kind of serum free medium for supporting HeLa cell attachment cultures | 王晓柯 | 2017-10-10 | — | — | CN | claimed |
| EP-0304004-B1 | Process for the production of sodium purines | BOEHRINGER INGELHEIM KG (DE) | 1993-11-03 | — | — | EP | claimed |
| WO-2020192302-A1 | PYRIMIDINE-CONTAINING TRI-SUBSTITUTED IMIDAZOLE COMPOUND AND APPLICATION THEREOF | 广州必贝特医药技术有限公司 | 2020-10-01 | — | — | WO | disclosed |
| CN-109294976-A | A kind of serum free medium for supporting HEK293 cell suspension cultures | 王晓柯 | 2019-02-01 | — | — | CN | disclosed |
| CN-105125522-B | A kind of hyaluronic acid-cationic drug ion pair particle | 四川大学 | 2018-08-21 | — | — | CN | disclosed |
| CN-108348894-A | Ozonolysis for compound activation and ozonolysis | 空气交叉股份有限公司 | 2018-07-31 | — | — | CN | disclosed |
| CN-107430124-A | The immunological detection and kit of mycoplasma pneumoniae | 滋吾堂有限公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-107407679-A | The immunological detection and kit of mycoplasma pneumoniae | 滋吾堂有限公司 | 2017-11-28 | — | — | CN | disclosed |
| CN-107236708-A | A kind of serum free medium for supporting HeLa cell attachment cultures | 王晓柯 | 2017-10-10 | — | — | CN | disclosed |
| EP-2467391-B1 | PROCESS FOR THE PREPARATION OF CLADRIBINE | SCINOPHARM KUNSHAN BIOCHEMICAL TECHNOLOGY CO LTD (CN) | 2016-04-27 | — | — | EP | disclosed |
| US-20020052491-A1 | Method for the production of 2-chloro-2' -deoxyadenosine (cladribine) and its 3,5-di-O-p-toluoyl derivative | GERSZBERG SZEPSEL (AR) | 2002-05-02 | — | — | US | disclosed |
| WO-2000064918-A1 | METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE | STERRENBELD BIOTECHNOLOGIE NORTH AMERICA, INC. (US) | 2000-11-02 | — | — | WO | disclosed |
| CN-1040114-C | Stereoselective glycosylation process | LILLY CO ELI (US) | 1998-10-07 | — | — | CN | disclosed |
| US-5532225-A | TREATMENT OF HERPES VIRUS | SRI INTERNATIONAL (US) | 1996-07-02 | — | — | US | disclosed |
| CN-1085560-A | Stereoselective glycosylation process | LILLY CO ELI (US) | 1994-04-20 | — | — | CN | disclosed |
| WO-1994003466-A1 | ACYCLIC PURINE PHOSPHONATE NUCLEOTIDE ANALOGS AS ANTIVIRAL AGENTS, AND RELATED SYNTHETIC METHODS | SRI INTERNATIONAL (US) | 1994-02-17 | — | — | WO | disclosed |
| EP-0304004-B1 | Process for the production of sodium purines | BOEHRINGER INGELHEIM KG (DE) | 1993-11-03 | — | — | EP | disclosed |
| EP-0304004-A1 | Process for the production of sodium purines | BOEHRINGER INGELHEIM KG (DE) | 1989-02-22 | — | — | EP | disclosed |
| EP-0304004-A1 | Process for the production of sodium purines | BOEHRINGER INGELHEIM KG (DE) | 1989-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052491-A1 | Method for the production of 2-chloro-2' -deoxyadenosine (cladribine) and its 3,5-di-O-p-toluoyl derivative | MTAP, TPMT, DCTD | KDM4A 505/4885KDM4B 564/4885KDM5C 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.